Acuta Capital Partners, LLC Taysha Gene Therapies, Inc. Transaction History
Acuta Capital Partners, LLC
- $122 Million
- Q1 2024
A detailed history of Acuta Capital Partners, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 3,333,333 shares of TSHA stock, worth $11.4 Million. This represents 7.82% of its overall portfolio holdings.
Number of Shares
3,333,333
Previous 3,589,333
7.13%
Holding current value
$11.4 Million
Previous $6.35 Million
50.57%
% of portfolio
7.82%
Previous 4.95%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
111Shares Held
109MCall Options Held
108KPut Options Held
158K-
Avoro Capital Advisors LLC New York, NY18.7MShares$64 Million0.65% of portfolio
-
Rtw Investments, LP New York, NY18.6MShares$63.8 Million0.86% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$30.9 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.92MShares$20.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.17MShares$17.7 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $166M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...